TY  - GEN
AU  - Totaro,R
AU  - Lugaresi,A
AU  - Bellantonio,P
AU  - Danni,M
AU  - Costantino,G
AU  - Gasperini,C
AU  - Florio,C
AU  - Pucci,E
AU  - Maddestra,M
AU  - Spitaleri,D
AU  - Lus,G
AU  - Ardito,B
AU  - Farina,D
AU  - Rossi,M
AU  - Di Carmine,C
AU  - Altobelli,E
AU  - Maccarone,B
AU  - Casalena,A
AU  - De Luca,G
AU  - Travaglini,D
AU  - Di Ioia,M
AU  - Di Tommaso,V
AU  - Fantozzi,R
AU  - Ruggieri,S
AU  - Provinciali,L
AU  - De Riso,S
AU  - Mundi,C
AU  - Fuiani,A
AU  - Galgani,S
AU  - Ruggieri,S
AU  - Maniscalco,G T
AU  - Giuliani,G
AU  - Cartechini,E
AU  - Petretta,V
AU  - Fratta,M
AU  - Alfieri,G
AU  - Gatto,M
AU  - Carolei,A
TI  - Natalizumab treatment in multiple sclerosis patients: a multicenter experience in clinical practice in Italy
SN  - 0394-6320
PY  - 2014///0811
KW  - Adult
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Disability Evaluation
KW  - Disease Progression
KW  - Disease-Free Survival
KW  - Female
KW  - Humans
KW  - Immunosuppressive Agents
KW  - Italy
KW  - Kaplan-Meier Estimate
KW  - Magnetic Resonance Imaging
KW  - Male
KW  - Middle Aged
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - diagnosis
KW  - Natalizumab
KW  - Product Surveillance, Postmarketing
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1177/039463201402700201
ER  -